semaglutide study near me Diabetes Drug Could Help Reduce Risk for Cardiovascular Events, Finds Semaglutide Improves Weight Loss in

Current Research Status and Future Directions Where We Are Now (2026) Retatrutide is currently in Phase 3 clinical development under Eli Lilly's TRIUMPH program, which includes multiple trials: TRIUMPH-3 Obesity without type 2 diabetes Evaluating 12mg vs 9mg vs placebo in adults with BMI 30 or 27 with comorbidities TRIUMPH-4 Obesity with type 2 diabetes Testing efficacy and safety in patients with both conditions (preliminary: 28.7% weight loss) MASLD/NASH Trials Metabolic dysfunction-associated steatotic liver disease Leveraging glucagon's liver fat reduction effects Cardiovascular Outcomes Long-term CV safety and benefits Following precedent of STEP and SURMOUNT trials for GLP-1 drugs Timeline to FDA Approval 2023: Phase 2 results published (NEJM) 2024-2026: Phase 3 trials ongoing (TRIUMPH program) 2026-2027: Anticipated FDA submission (if trials successful) 2027-2028: Potential FDA approval and commercial launch What Researchers Are Watching The main questions Phase 3 needs to answer: Long-term efficacy: Does weight loss plateau or continue beyond 48 weeks

Some people also experience headaches, increased infections, rapid heart rate, dizziness, and indigestion

The presence of a potential anatomical cause for weight regain did also not significantly change the efficacy on body weight loss of GLP1-RA, which supports the use of GLP1-RA in patients with such anatomical changes

Conclusion The troubleshooting process is not just about fixing mistakes

The results are in ng/mL (nanograms per milliliter)